Pain reduction with oral and intravenous ibandronate treatment for metastatic bone disease of breast cancer

Bone ◽  
2006 ◽  
Vol 38 (3) ◽  
pp. 77-78
Author(s):  
A.A. Kurth ◽  
J. Seraphin ◽  
F. Schütze ◽  
A. Nusch ◽  
I. Schäfer ◽  
...  
2017 ◽  
Vol 27 (6) ◽  
pp. 729-736 ◽  
Author(s):  
Dimitrios Filippiadis ◽  
Andreas F. Mavrogenis ◽  
Argyro Mazioti ◽  
Konstantinos Palialexis ◽  
Panayiotis D. Megaloikonomos ◽  
...  

1999 ◽  
Vol 17 (8) ◽  
pp. 2381-2381 ◽  
Author(s):  
Holger Schirrmeister ◽  
Albrecht Guhlmann ◽  
Jörg Kotzerke ◽  
Claudia Santjohanser ◽  
Thorsten Kühn ◽  
...  

PURPOSE: Previous studies have shown that bone metastases are revealed by magnetic resonance imaging (MRI) or bone marrow scintigraphy several months before they are visible by conventional bone scintigraphy (BS). We present a new approach for detecting bone metastases in patients with breast cancer. We compared findings obtained with fluoride ion (F-18) and positron emission tomography (PET) with those obtained with conventional BS. PATIENTS AND METHODS: Thirty-four breast cancer patients were prospectively examined using F-18–PET and conventional BS. F-18–PET and BS were performed within 3 weeks of each other. Metastatic bone disease was previously known to be present in six patients and was suspected (bone pain or increasing levels of tumor markers, Ca2+, alkaline phosphatase) in 28 patients. Both imaging modalities were compared by patient-by-patient analysis and lesion-by-lesion analysis, using a five-point scale for receiver operating characteristic (ROC) curve analysis. A panel of reference methodswas used, including MRI (28 patients), planar x-ray (17 patients), and spiral computed tomography (four patients). RESULTS: With F-18–PET, 64 bone metastases were detected in 17 patients. Only 29 metastases were detected in 11 patients with BS. As a result of F-18–PET imaging, clinical management was changed in four patients (11.7%). For F-18–PET, the area under the ROC curve was 0.99 on a lesion basis (for BS, it was 0.74; P < .05) and 1.00 on a patient basis (for BS, it was 0.82; P < .05). CONCLUSION: F-18–PET demonstrates a very early bone reaction when small bone marrow metastases are present, allowing accurate detection of breast cancer bone metastases. This accurate detection has a significant effect on clinical management, compared with the effect on management brought about by detection with conventional BS.


Bone ◽  
2006 ◽  
Vol 38 (3) ◽  
pp. 83 ◽  
Author(s):  
I. Schäfer ◽  
J. Seraphin ◽  
F. Schütze ◽  
A. Nusch ◽  
H. Meden ◽  
...  

2019 ◽  
Vol 12 (4) ◽  
pp. 77-82
Author(s):  
Heru Hermantrie ◽  
Pranajaya Dharma Kadar ◽  
Andriandi ◽  
Aznan Lelo

Objective -The aim of this study was to determining the survival rate of patient with metastatic bone disease in Haji Adam Malik Hospital Medan. Material and Methods-The aim of this retrospective study is to determine the survival rate of metastatic bone disease patients. Fifty-five patients who diagnosed of metastatic bone disease during January 2012 – December 2017 were entered the inclusion criteria were ask and demographic data were also recorded to evaluate further associated with primary lesion, and surviving status. Survival rate was assessed by Kapplan – Meier Curve. Results- From January 2012 to December 2017, a total 55 metastatic bone disease patients were aged 43-77 years. Breast cancer (40%) was the most common primary cancer, with the lowest survival rate in cervic (10 months). Overall, patients who treat surgically and chemotherapy have survival rate 17 months. Conclusion-This study revealed that female (33 patients) have 15 months of survival rate and mael (22 patients) have 18 months of survival rate. Breast was the most common primary location tumor (40%) and have highest survival rate (20 months). Cervix was the lowest survival rate (10 months) Overall patients who underwent surgical and chemotherapy have survival rate in 17 months.


Sign in / Sign up

Export Citation Format

Share Document